PE20250123A1 - Inhibidores de cdk2 - Google Patents
Inhibidores de cdk2Info
- Publication number
- PE20250123A1 PE20250123A1 PE2023003487A PE2023003487A PE20250123A1 PE 20250123 A1 PE20250123 A1 PE 20250123A1 PE 2023003487 A PE2023003487 A PE 2023003487A PE 2023003487 A PE2023003487 A PE 2023003487A PE 20250123 A1 PE20250123 A1 PE 20250123A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- halo
- optionally substituted
- inter alia
- groups
- Prior art date
Links
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 title abstract 2
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion proporciona compuestos con la formula (I) o una sal farmaceuticamente aceptable de este, donde R1 es alquilo C1-C4 opcionalmente sustituido con 1 a 4 halo; R2 es alquilo C1-C4, entre otros; R3 es H, alquilo C1-C4, entre otros; o R2 y R3 se toman junto con el atomo de C al que estan unidos para formar el Anillo B, donde el Anillo B es cicloalquilo C3-C10 o heterociclilo de 4 a 12 miembros, entre otros; R4 es H o alquilo C1-C4 opcionalmente sustituido con 1 a 4 grupos seleccionados cada uno independientemente de halo y OH; y R5 es H, halo, CN y alquilo C1-C4, donde el alquilo C1-C4 esta opcionalmente sustituido con 1 a 4 grupos seleccionados cada uno independientemente de halo y OH. El compuesto con la formula (I) o una sal farmaceuticamente aceptable permite tratar una enfermedad o trastorno asociado con CDK2 como el cancer y entre estos el cancer de mama.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163215901P | 2021-06-28 | 2021-06-28 | |
| PCT/US2022/035122 WO2023278326A1 (en) | 2021-06-28 | 2022-06-27 | Cdk2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20250123A1 true PE20250123A1 (es) | 2025-01-16 |
Family
ID=82655170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023003487A PE20250123A1 (es) | 2021-06-28 | 2022-06-27 | Inhibidores de cdk2 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11932648B2 (es) |
| EP (1) | EP4363423A1 (es) |
| JP (1) | JP2024524373A (es) |
| KR (1) | KR20240046167A (es) |
| CN (1) | CN117897384A (es) |
| AR (1) | AR126251A1 (es) |
| AU (1) | AU2022301047A1 (es) |
| CA (1) | CA3223223A1 (es) |
| CL (1) | CL2023003965A1 (es) |
| CO (1) | CO2024000237A2 (es) |
| CR (1) | CR20230598A (es) |
| DO (1) | DOP2023000280A (es) |
| EC (1) | ECSP24006831A (es) |
| IL (1) | IL309118A (es) |
| MX (1) | MX2024000230A (es) |
| PE (1) | PE20250123A1 (es) |
| TW (1) | TW202317574A (es) |
| UY (1) | UY39832A (es) |
| WO (1) | WO2023278326A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL308314A (en) | 2021-05-07 | 2024-01-01 | Kymera Therapeutics Inc | CDK2 compounds and their uses |
| IL309118A (en) * | 2021-06-28 | 2024-02-01 | Blueprint Medicines Corp | CDK2 inhibitors |
| AU2023393410A1 (en) | 2022-12-16 | 2025-07-31 | Astrazeneca Ab | 2,6,9-trisubstituted purines |
| JP2026501699A (ja) * | 2023-01-04 | 2026-01-16 | ブループリント メディシンズ コーポレイション | Ｃｄｋ２阻害剤 |
| JP2026501701A (ja) * | 2023-01-04 | 2026-01-16 | ブループリント メディシンズ コーポレイション | Ｃｄｋ２阻害剤の固体形態 |
| JP2026501702A (ja) * | 2023-01-04 | 2026-01-16 | ブループリント メディシンズ コーポレイション | Ｃｄｋ２阻害剤 |
| CN120835885A (zh) * | 2023-01-04 | 2025-10-24 | 缆图药品公司 | Cdk2抑制剂 |
| EP4661874A1 (en) | 2023-02-10 | 2025-12-17 | Blueprint Medicines Corporation | The cdk2 inhibitor blu-222 for treatment of cancer |
| UY40638A (es) | 2023-02-17 | 2024-08-30 | Novartis Ag | Inhibidores de quinasa dependientes de ciclina (cdk2) |
| WO2025188779A1 (en) | 2024-03-04 | 2025-09-12 | Blueprint Medicines Corporation | Cdk2 inhibitors for treatment of cancer |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ2003468A3 (cs) | 2000-08-31 | 2004-05-12 | Pfizeráproductsáinc | Deriváty pyrazolu a jejich použití jako inhibitorů proteinkinázy |
| ES2242771T5 (es) | 2000-09-15 | 2011-10-14 | Vertex Pharmaceuticals Incorporated | Compuestos de pirazol útiles como inhibidores de proteína quinasas. |
| CN102250071A (zh) | 2000-12-21 | 2011-11-23 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的吡唑化合物 |
| EP1706400A1 (en) | 2004-01-09 | 2006-10-04 | Novartis AG | Phenyl- 4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl -amine derivatives as igf-ir inhibitors |
| US8362031B2 (en) | 2004-08-20 | 2013-01-29 | University Of Kansas | Lonidamine analogues and treatment of polycystic kidney disease |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| AU2006283592A1 (en) | 2005-08-22 | 2007-03-01 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
| DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
| KR20110049217A (ko) | 2009-11-04 | 2011-05-12 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자 |
| KR20120063283A (ko) | 2010-12-07 | 2012-06-15 | 제일약품주식회사 | 신규한 피라졸로 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| WO2014181137A1 (en) | 2013-05-10 | 2014-11-13 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors |
| CN105814057B (zh) | 2013-07-31 | 2019-05-03 | 默克专利有限公司 | 用作btk抑制剂的嘧啶、吡啶和吡嗪及其用途 |
| WO2016057322A1 (en) | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
| SI3302448T1 (sl) | 2015-06-04 | 2024-03-29 | Aurigene Oncology Limited | Substituirani heterociklični derivati kot inhibitorji cdk |
| US11459308B2 (en) | 2016-12-05 | 2022-10-04 | Microbiotix, Inc. | Broad spectrum inhibitors of filoviruses |
| EP3768680A1 (en) | 2018-03-21 | 2021-01-27 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
| GB201808093D0 (en) | 2018-05-18 | 2018-07-04 | Enterprise Therapeutics Ltd | Compounds |
| TWI740288B (zh) | 2018-11-27 | 2021-09-21 | 大陸商江蘇豪森藥業集團有限公司 | 含氮雜芳類衍生物調節劑、其製備方法和應用 |
| AU2019388929A1 (en) * | 2018-11-30 | 2021-07-22 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Heteroaromatic derivatives for use as regulator, preparation method therefor and use thereof |
| MY210283A (en) | 2019-01-31 | 2025-09-08 | Pfizer | 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2 |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| CA3143525A1 (en) | 2019-06-28 | 2020-12-30 | Gb002, Inc. | Heterocyclic kinase inhibitors and products and uses thereof |
| WO2021072232A1 (en) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
| WO2022061155A1 (en) | 2020-09-17 | 2022-03-24 | The Translational Genomics Research Institute | Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7 |
| US20240261297A1 (en) | 2021-05-20 | 2024-08-08 | St. John's Cancer Institute | Anti-cdk inhibitors for cancer treatment |
| WO2022266190A1 (en) | 2021-06-16 | 2022-12-22 | Blueprint Medicines Corporation | Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| IL309118A (en) | 2021-06-28 | 2024-02-01 | Blueprint Medicines Corp | CDK2 inhibitors |
| WO2023092088A1 (en) | 2021-11-19 | 2023-05-25 | Blueprint Medicines Corporation | Cdk2 inhibitors and methods of making and using same |
-
2022
- 2022-06-27 IL IL309118A patent/IL309118A/en unknown
- 2022-06-27 JP JP2023580454A patent/JP2024524373A/ja active Pending
- 2022-06-27 EP EP22744613.5A patent/EP4363423A1/en active Pending
- 2022-06-27 UY UY0001039832A patent/UY39832A/es unknown
- 2022-06-27 WO PCT/US2022/035122 patent/WO2023278326A1/en not_active Ceased
- 2022-06-27 MX MX2024000230A patent/MX2024000230A/es unknown
- 2022-06-27 TW TW111123974A patent/TW202317574A/zh unknown
- 2022-06-27 KR KR1020247003175A patent/KR20240046167A/ko active Pending
- 2022-06-27 PE PE2023003487A patent/PE20250123A1/es unknown
- 2022-06-27 AU AU2022301047A patent/AU2022301047A1/en active Pending
- 2022-06-27 US US17/850,453 patent/US11932648B2/en active Active
- 2022-06-27 CA CA3223223A patent/CA3223223A1/en active Pending
- 2022-06-27 CR CR20230598A patent/CR20230598A/es unknown
- 2022-06-27 CN CN202280057725.7A patent/CN117897384A/zh active Pending
- 2022-06-27 AR ARP220101677A patent/AR126251A1/es unknown
-
2023
- 2023-02-08 US US18/166,178 patent/US11970498B2/en active Active
- 2023-12-18 DO DO2023000280A patent/DOP2023000280A/es unknown
- 2023-12-28 CL CL2023003965A patent/CL2023003965A1/es unknown
-
2024
- 2024-01-12 CO CONC2024/0000237A patent/CO2024000237A2/es unknown
- 2024-01-25 EC ECSENADI20246831A patent/ECSP24006831A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY39832A (es) | 2023-01-31 |
| CL2023003965A1 (es) | 2024-12-06 |
| JP2024524373A (ja) | 2024-07-05 |
| US11932648B2 (en) | 2024-03-19 |
| ECSP24006831A (es) | 2024-07-31 |
| US20240383902A1 (en) | 2024-11-21 |
| AR126251A1 (es) | 2023-10-04 |
| TW202317574A (zh) | 2023-05-01 |
| CN117897384A (zh) | 2024-04-16 |
| US20230159535A1 (en) | 2023-05-25 |
| DOP2023000280A (es) | 2024-03-28 |
| CA3223223A1 (en) | 2023-01-05 |
| MX2024000230A (es) | 2024-04-01 |
| IL309118A (en) | 2024-02-01 |
| EP4363423A1 (en) | 2024-05-08 |
| KR20240046167A (ko) | 2024-04-08 |
| US20230322791A1 (en) | 2023-10-12 |
| WO2023278326A1 (en) | 2023-01-05 |
| CR20230598A (es) | 2024-04-25 |
| AU2022301047A1 (en) | 2024-01-04 |
| US11970498B2 (en) | 2024-04-30 |
| CO2024000237A2 (es) | 2024-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20250123A1 (es) | Inhibidores de cdk2 | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| PE20180451A1 (es) | Nuevos compuestos biciclicos como inhibidores de atx | |
| AR120080A1 (es) | Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos | |
| AR105836A1 (es) | Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk | |
| CU20200046A7 (es) | Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47 | |
| AR114803A1 (es) | Compuestos de 4-aminoisoindolin-1,3-diona sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos | |
| AR115993A2 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| PE20240775A1 (es) | Compuestos antivirales | |
| PE20200700A1 (es) | Compuestos macrociclicos y usos de los mismos | |
| AR106070A1 (es) | Benzamidas sustituidas con isoxazolina como insecticidas | |
| ECSP19043231A (es) | Inhibidores de la tirosina quinasa de bruton | |
| PE20242071A1 (es) | Compuestos moduladores de diacilglicerol quinasa | |
| AR092809A1 (es) | 3,5-diaminopirazol como inhibidor de quinasa | |
| AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| PE20251601A1 (es) | Inhibidores de kif18a y usos de estos | |
| AR115936A1 (es) | Compuestos útiles en terapia del vih | |
| PE20190964A1 (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica | |
| PE20200333A1 (es) | Compuestos y metodos para tratar infecciones bacterianas | |
| AR124189A1 (es) | Compuestos y procedimientos de uso de los mismos | |
| AR109088A1 (es) | Carbamato de quinabactina | |
| CO2020010042A2 (es) | Compuestos de alquinileno sustituidos como agentes anticancerígenos | |
| AR102019A1 (es) | (r)-3-((3s,4s)-3-fluoro-4-(4-hidroxifenil)piperidin-1-il)-1-(4-metilbencil)pirrolidin-2-ona y sus profármacos para el tratamiento de trastornos psiquiátricos | |
| AR109712A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa |